The company that sells Ozempic and Wegovy, drugs known for promoting easy weight loss, is now selling the products at Costco.

The maker of the weight loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of the blockbuster medications.

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the drugs affect the body beyond just weight loss. But one of the more anticipated studies exploring how they impact Alzheimer’s disease has found no meaningful effect, Novo Nordisk said in a press release on Nov. 24

The cash price for popular weight-loss medications Wegovy and and the medication authorized for people with type 2 diabetes Ozempic are dropping by 30% in U.S. on Monday, according to Novo Nordisk, the Danish pharmaceutical company that manufactures both drugs.

Novo and Lilly just slashed prices on GLP-1 weight-loss drugs that recently cost over $1,000 a month. What happened?

Novo Nordisk said on Monday it would lower the U.S. price of its injectable Wegovy obesity drug and pledged to go "all in" on its upcoming oral weight-loss pill, as the firm races to claw back lost ground in the lucrative market.

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy the drugs directly.

The Danish company is trying to regain market share from Eli Lilly — which makes Mounjaro and Zepbound — by making its weight loss drug considerably cheaper. Zepbound jumped in popularity after clinical trials showed it was more effective than Wegovy and had fewer complaints about side effects.

U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss drugs like Wegovy and Zepbound from patients who lose only moderate amounts of weight at best,